Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
2017/07/12 by Remy B. Verheijen, Huixin Yu, Jan H.M. Schellens +4 · 29 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Chronic Myeloid Leukemia Treatments #Chronic Lymphocytic Leukemia Research #PI3K/AKT/mTOR signaling in cancer
paper · pdf · doi:10.1002/cpt.787
Abstract
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
Cited by
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
- Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
- Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
- Clinically relevant drug interactions with multikinase inhibitors: a review. [europepmc]
- Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study. [europepmc]
- Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. [europepmc]
- Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. [europepmc]
- New Oral Anti-Cancer Drugs and Medication Safety. [europepmc]
- Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. [europepmc]
- Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. [europepmc]
- The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. [europepmc]
- Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. [europepmc]
- Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. [europepmc]
- Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma. [europepmc]
- Therapeutic drug monitoring of oral targeted antineoplastic drugs. [europepmc]
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. [europepmc]
- Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors. [europepmc]
- Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR + /HER2 - Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). [europepmc]
- Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. [europepmc]
- A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs. [europepmc]
- Precision Dosing of Targeted Therapies Is Ready for Prime Time. [europepmc]
- Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics. [europepmc]
- Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples. [europepmc]
- Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. [europepmc]
- An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer. [europepmc]
- Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer. [europepmc]
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. [europepmc]
- Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics. [europepmc]
Related